Study of VDJ001 for idiopathic multicentric Castleman disease
This trial tests a new medicine called VDJ001 for people with idiopathic multicentric Castleman disease (iMCD), a rare condition causing enlarged lymph nodes and symptoms like fever, fatigue, weight loss, and poor appetite. The goal is to see if VDJ001 can help control the disease and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multicentric Castleman disease confirmed by biopsy and have symptoms like fever, fatigue, weight loss, or poor appetite.
- Your blood counts and liver/kidney function meet certain levels.
- You are able to perform daily activities with some help (ECOG score 0–2).
- If you are on steroids, your dose has been stable or reduced for 4 weeks before starting.
- You agree to use effective birth control during the trial and for 6 months after the last dose.
- You have not had certain previous treatments or health conditions (like HIV, active infections, recent heart problems, or other cancers in the last 5 years).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
This trial tests a combination of four medications (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) for people with monoclonal immunoglobulin deposition disease (MIDD), a condition where abnormal proteins build up in organs. The goal is to see if this treatment can help without prior harsh therapies.
This study tests an investigational drug called KSVCBD for people with certain autoimmune diseases that haven't improved with standard treatments. It aims to see if the drug is safe and if it can help reduce symptoms.
This trial tests the drug ruxolitinib for people with idiopathic multicentric Castleman disease (iMCD) whose symptoms are not well controlled by standard anti-IL-6 therapy. Ruxolitinib is a pill taken by mouth that may help reduce inflammation and improve symptoms.
This trial tests a medication called nintedanib, which may help shrink or control the growth of Castleman disease when surgery isn't possible. It is a pill taken by mouth, and the goal is to see if it can help people with this condition.
This study looks at how KSHV-associated multicentric Castleman disease naturally progresses over time, without necessarily testing a new treatment. It may help doctors better understand the disease and what changes to watch for, which could guide future care.
Hear when a new Anti IL-6R trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.